Drugs in Dev. Cardiology/Vascular Diseases
IND Enabling
Canada 
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Repair Biotechnologies
Deal Size : $107.0 million
Deal Type : Licensing Agreement
Repair Biotech, Genevant Partner on mRNA-LNP Therapy for Atherosclerosis
Details : Under the license agreement, Genevant will grant Repair a nonexclusive worldwide license to certain LNP technology to exploit CDP mRNA products for a specified field that includes atherosclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Repair Biotechnologies
Deal Size : $107.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
Details : The Company also confirmed in its own murine cortical neuron outgrowth preclinical study, that AP-188 (N,N-Dimethyltryptamine), in sub-psychedelic doses, increased the growth of cortical neurons by up to 40% compared to control.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
Details : AP-188 (N,N-Dimethyltryptamine), or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A novel salt form of AP-188 (N, N-dimethyltryptamine), a hallucinogenic tryptamine drug, is a new and separate structure from the original compound, helps mitigate tissue damage and promote neurogenesis demonstrated in preclinical studies.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company received positive feedback from the UK MHRA for its planned Phase 1 DMT Stroke study for AP-188 (N,N-Dimethyltryptamine), a hallucinogenic tryptamine drug for the treatment of mental health disorders.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Details : The Phase 1 will investigate safety, dose, and the pharmacokinetics of DMT, while the Phase 2a part will additionally examine the use of DMT as an adjunctive treatment to Constraint-Induced Movement Therapy for the treatment of upper-limb dysfunction in ...
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
LQT Therapeutics Announces Closing of US$19M Series A Financing
Details : LQTT is advancing a series of in- licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AP-188 (“N,N-Dimethyltryptamine or “DMT”), increased the growth of cortical neurons by 40% with statistical significance in one arm of the study, when compared to control. Algernon also reports that the increased growth was achieved with a sub hall...
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company announced preclinical study of AP-188 (“N, N-Dimethyltryptamine) in stroke patients which is now underway with Charles River Laboratories.The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenou...
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 17, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Algernon has filed new provisional patents for new forms of N,N-Dimethyltryptamine (DMT), in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint Ind...
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
